 |
40 Products |  |
109 Diseases | | 40 Products |
|
37 Trials |  |
1900 News |  |
| «12...891011121314151617181920» |
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Biomarker, Trial withdrawal, Metastases: Tivozanib + Gemcitabine in Metastatic RCC (clinicaltrials.gov) - Jun 16, 2013
P2, N=0, Withdrawn, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Withdrawn
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Biomarker, Enrollment change, Metastases: Tivozanib + Gemcitabine in Metastatic RCC (clinicaltrials.gov) - Jun 16, 2013
P2, N=0, Withdrawn, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Withdrawn N=40 --> 0
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Enrollment open: Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov) - Jun 13, 2013
P2, N=30, Recruiting, Sponsor: Northwestern University
N=40 --> 0 Not yet recruiting --> Recruiting
- || tigulixostat (LC350189) / LG Chem
Enrollment change: Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189 (clinicaltrials.gov) - Jun 9, 2013
P1, N=129, Completed, Sponsor: LG Life Sciences
Not yet recruiting --> Recruiting N=102 --> 129
- ||| tigulixostat (LC350189) / LG Chem
Trial completion: Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189 (clinicaltrials.gov) - Jun 9, 2013
P1, N=129, Completed, Sponsor: LG Life Sciences
N=102 --> 129 Recruiting --> Completed
- | Euvax B (recombinant hepatitis B vaccine) / LG Chem, Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi
New P1/2 trial: Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine (clinicaltrials.gov) - Jun 2, 2013
P1/2, N=350, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
New P2 trial: Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov) - May 13, 2013
P2, N=30, Recruiting, Sponsor: Northwestern University
- ||| Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Enrollment closed, Combination therapy, Metastases: A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy (clinicaltrials.gov) - May 8, 2013
P2, N=265, Active, not recruiting, Sponsor: Astellas Pharma Inc
Recruiting --> Completed Recruiting --> Active, not recruiting
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
New P2 trial: Tivozanib for Recurrent Glioblastoma (clinicaltrials.gov) - May 1, 2013
P2, N=21, Active, not recruiting, Sponsor: Massachusetts General Hospital
- | ZemiSU (gemigliptin/glimepiride) / LG Chem
Trial completion: Pharmacokinetic Drug Interaction Study Between Gemigliptin and Glimepiride in Healthy Male Subjects (clinicaltrials.gov) - Apr 21, 2013
P1, N=27, Completed, Sponsor: LG Life Sciences
Recruiting --> Active, not recruiting Recruiting --> Completed
- Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz
New P1/2 trial, Surgery, Metastases: Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Apr 16, 2013
P1/2, N=49, Recruiting, Sponsor: Roswell Park Cancer Institute
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Biomarker, New P2 trial, Metastases: Tivozanib + Gemcitabine in Metastatic RCC (clinicaltrials.gov) - Apr 15, 2013
P2, N=0, Withdrawn, Sponsor: Dana-Farber Cancer Institute
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial initiation date, Metastases: A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat (clinicaltrials.gov) - Apr 7, 2013
P1/2, N=0, Withdrawn, Sponsor: University of Utah
Recruiting --> Completed Initiation date: Feb 2013 --> Nov 2013
- | Gemiglo (gemigliptin) / Sanofi, LG Chem
New P1 trial: Pharmacokinetic Drug Interaction Study Between Gemigliptin and Irbesartan After Oral Administration in Healthy Male Subjects (clinicaltrials.gov) - Apr 4, 2013
P1, N=30, Enrolling by invitation, Sponsor: LG Life Sciences
- | ZemiStatin (gemigliptin/rosuvastatin FDC) / LG Chem
New P1 trial: Study for Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Rosuvastatin (clinicaltrials.gov) - Apr 2, 2013
P1, N=30, Completed, Sponsor: LG Life Sciences
- |||| Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Enrollment open, Metastases: A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas (clinicaltrials.gov) - Mar 13, 2013
P2, N=54, Recruiting, Sponsor: Northwestern University
Initiation date: Feb 2013 --> Nov 2013 Not yet recruiting --> Recruiting
- TNFcept (etanercept biosimilar) / LG Chem, Mochida
Trial completion: Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25mg With Those of Enbrel® (clinicaltrials.gov) - Mar 11, 2013
P1, N=0, Completed, Sponsor: LG Life Sciences
Not yet recruiting --> Recruiting Recruiting --> Completed
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
New P2 trial, Metastases: Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer (clinicaltrials.gov) - Mar 6, 2013
P2, N=22, Recruiting, Sponsor: Emory University
- ||||| Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
New P2 trial, Metastases: A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas (clinicaltrials.gov) - Jan 30, 2013
P2, N=54, Recruiting, Sponsor: Northwestern University
- ||||||| Hyruan Plus (sodium hyaluronate) / LG Chem
Trial completion: Efficacy and Safety of LBSA0103 Versus Hyruan Plus Injection in Patients With Knee Osteoarthritis (clinicaltrials.gov) - Jan 15, 2013
P3, N=287, Completed, Sponsor: LG Life Sciences
Recruiting --> Completed Active, not recruiting --> Completed
- | ZemiSU (gemigliptin/glimepiride) / LG Chem
New P1 trial: Pharmacokinetic Drug Interaction Study Between Gemigliptin and Glimepiride in Healthy Male Subjects (clinicaltrials.gov) - Jan 13, 2013
P1, N=27, Completed, Sponsor: LG Life Sciences
- | Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
New P1 trial: Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets) (clinicaltrials.gov) - Dec 9, 2012
P1, N=24, Completed, Sponsor: LG Life Sciences
- |||| Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz
Biomarker, Trial completion, Metastases: A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Dec 6, 2012
P2, N=105, Completed, Sponsor: AVEO Pharmaceuticals, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
New P2 trial, Combination therapy, IO biomarker, Metastases: BATON-BC: Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - Dec 6, 2012
P2, N=147, Terminated, Sponsor: AVEO Pharmaceuticals, Inc.
- ||| MIT-001 / MitoImmune Therap
New P1 trial: Study to Investigate the Safety and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects (clinicaltrials.gov) - Nov 27, 2012
P1, N=89, Completed, Sponsor: LG Life Sciences
- Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
New P1/2 trial, Metastases: A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat (clinicaltrials.gov) - Nov 14, 2012
P1/2, N=0, Withdrawn, Sponsor: University of Utah
- TNFcept (etanercept biosimilar) / LG Chem, Mochida
New P1 trial: Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25mg With Those of Enbrel® (clinicaltrials.gov) - Nov 12, 2012
P1, N=0, Completed, Sponsor: LG Life Sciences
- ||||| Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
P3 data, Enrollment change: An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301). (clinicaltrials.gov) - Oct 9, 2012
P3, N=350, Active, not recruiting, Sponsor: AVEO Pharmaceuticals, Inc.
Active, not recruiting --> Completed N=500 --> 350
- ||||| Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
New P2 trial, Metastases: TAURUS: A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC (clinicaltrials.gov) - Aug 26, 2012
P2, N=160, Completed, Sponsor: AVEO Pharmaceuticals, Inc.
- | Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial completion, Metastases: Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers (clinicaltrials.gov) - Aug 23, 2012
P1, N=30, Completed, Sponsor: AVEO Pharmaceuticals, Inc.
N=500 --> 350 Active, not recruiting --> Completed
- ||||| Espogen (epoetin alfa biosimilar) / LG Chem
New P2 trial: Erythropoietin Therapy for Children With Cerebral Palsy (clinicaltrials.gov) - Jul 24, 2012
P2, N=80, Not yet recruiting, Sponsor: Bundang CHA Hospital
- Espogen (epoetin alfa biosimilar) / LG Chem
Trial initiation date: Erythropoietin Therapy for Children With Cerebral Palsy: Phase 1 (clinicaltrials.gov) - Jul 9, 2012
P1, N=11, Completed, Sponsor: MinYoung Kim, M.D.
Active, not recruiting --> Completed Initiation date: Mar 2012 --> Jun 2012
- | Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
New P1 trial: A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function (clinicaltrials.gov) - Jun 26, 2012
P1, N=44, Completed, Sponsor: AVEO Pharmaceuticals, Inc.
- | Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial completion: A Phase 1 Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Tivozanib in Healthy Subjects (clinicaltrials.gov) - May 31, 2012
P1, N=30, Completed, Sponsor: AVEO Pharmaceuticals, Inc.
Initiation date: Mar 2012 --> Jun 2012 Active, not recruiting --> Completed
- | Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial completion: A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy Subjects (clinicaltrials.gov) - May 31, 2012
P1, N=30, Completed, Sponsor: AVEO Pharmaceuticals, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial completion: A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Tivozanib (AV-951) in Healthy Subjects (clinicaltrials.gov) - May 31, 2012
P1, N=30, Completed, Sponsor: AVEO Pharmaceuticals, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Shinbaro (GCSB-5) / GC Pharma, LG Chem
New P4 trial: To Evaluate the Safety of 'Shinbaro Capsule'in Patients With Osteoarthritis (clinicaltrials.gov) - May 21, 2012
P4, N=761, Completed, Sponsor: Green Cross Corporation
- AV-203 / LG Chem
New P1 trial, Metastases: A Phase 1 Dose Escalation Study of AV-203, an ERBB3 Inhibitory Antibody, in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - May 21, 2012
P1, N=90, Active, not recruiting, Sponsor: AVEO Pharmaceuticals, Inc.
- Gemiglo (gemigliptin) / Sanofi, LG Chem
New P1 trial: Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C] LC15-0444 (clinicaltrials.gov) - May 20, 2012
P1, N=6, Completed, Sponsor: LG Life Sciences
- |||||||||| Gemiglo (gemigliptin) / Sanofi, LG Chem
New P3 trial: Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes (clinicaltrials.gov) - May 16, 2012
P3, N=425, Completed, Sponsor: LG Life Sciences
- |||||||||| Gemiglo (gemigliptin) / Sanofi, LG Chem
New P3 trial: Phase 3 Trial to Evaluate the Efficacy and Safety of LC15-0444 in Patients With Type 2 Diabetes (clinicaltrials.gov) - May 16, 2012
P3, N=189, Completed, Sponsor: LG Life Sciences
- | Espogen (epoetin alfa biosimilar) / LG Chem
New P1 trial: Erythropoietin Therapy for Children With Cerebral Palsy: Phase 1 (clinicaltrials.gov) - Apr 24, 2012
P1, N=11, Completed, Sponsor: MinYoung Kim, M.D.
- ||| Besivo (besifovir) / Gilead, LG Chem, Ildong
Enrollment closed: Long-term Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B (clinicaltrials.gov) - Apr 12, 2012
P2, N=115, Active, not recruiting, Sponsor: LG Life Sciences
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- |||| Besivo (besifovir) / Gilead, LG Chem, Ildong
Trial completion: Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B (clinicaltrials.gov) - Apr 12, 2012
P2b, N=115, Completed, Sponsor: LG Life Sciences
Enrolling by invitation --> Active, not recruiting Active, not recruiting --> Completed
- | ficlatuzumab (AV-299) / LG Chem
Trial completion, Metastases: A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases (clinicaltrials.gov) - Apr 10, 2012
P1, N=19, Completed, Sponsor: AVEO Pharmaceuticals, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ficlatuzumab (AV-299) / LG Chem
Trial withdrawal: SCH-900105 in Recurrent Glioblastoma (clinicaltrials.gov) - Feb 16, 2012
P1, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Terminated --> Withdrawn
- |||||||||| Shinbaro (GCSB-5) / GC Pharma, LG Chem
New P3 trial: Efficacy and Safety of Shinbaro Capsule (clinicaltrials.gov) - Feb 11, 2012
P3, N=198, Completed, Sponsor: Green Cross Corporation
- Espogen (epoetin alfa biosimilar) / LG Chem
Trial completion, Combination therapy: Allogenic Umbilical Cord Blood and Erythropoietin Combination Therapy for Cerebral Palsy (clinicaltrials.gov) - Jan 29, 2012
P=N/A, N=105, Completed, Sponsor: Sung Kwang Medical Foundation
Terminated --> Withdrawn Active, not recruiting --> Completed
- |||||||||| Hyruan Plus (sodium hyaluronate) / LG Chem
New P3 trial: Efficacy and Safety of LBSA0103 Versus Hyruan Plus Injection in Patients With Knee Osteoarthritis (clinicaltrials.gov) - Jan 12, 2012
P3, N=287, Completed, Sponsor: LG Life Sciences
- | Gemiglo (gemigliptin) / Sanofi, LG Chem
Trial completion: Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of LC15-0444 and Metformin After Oral Administration in Healthy Male Subjects (clinicaltrials.gov) - Dec 28, 2011
P1, N=30, Completed, Sponsor: LG Life Sciences
Active, not recruiting --> Completed Recruiting --> Completed